Glycosylated neuropeptides: A new vista for neuropsychopharmacology?

Medicinal Research Reviews - Tập 25 Số 5 - Trang 557-585 - 2005
Robin Polt1, M. Dhanasekaran1, Charles M. Keyari1
1The Carl S. Marvel Laboratories, Department of Chemistry, The University of Arizona, Tucson, Arizona 85721

Tóm tắt

AbstractThe application of endogenous neuropeptides (e.g., enkephalins) as analgesics has been retarded by their poor stability in vivo and by their inability to effectively penetrate the blood–brain barrier (BBB). Effective BBB transport of glycosylated enkephalins has been demonstrated in several labs now. Analgesia (antinociception) levels greater than morphine, and with reduced side effects have been observed for several glycopeptides related to enkephalin. Somewhat paradoxically, enhanced BBB transport across this lipophilic barrier is achieved by attaching water‐soluble carbohydrate groups to the peptide moieties to produce biousian glycopeptides that can be either water‐soluble or membrane bound. Transport is believed to rely on an endocytotic mechanism (transcytosis), and allows for systemic delivery and transport of the water‐soluble glycopeptides. Much larger endorphin/dynorphin glycopeptide analogs bearing amphipathic helix address regions also have been shown to penetrate the BBB in mice. This holds forth the possibility of transporting much larger neuropeptides across the BBB, which may encompass a wide variety of receptors beyond the opioid receptors. © 2005 Wiley Periodicals, Inc.

Từ khóa


Tài liệu tham khảo

Gutstein HB, 2001, Goodman & Gilman's the pharmacological basis of therapeutics, 569

Kririkos PG, 1968, A history of opium in antiquity, J Am Pharm Assn, 8, 446

Benedetti C, 1990, The history of opium and its derivatives in advances in pain research and therapy, 1

(d)http://opioids.com/timeline/.

10.1073/pnas.90.12.5391

Gutstein HB, 2001, Goodman and Gilman's the pharmacological basis of therapeutics, 569

Hannon JP, 1991, Cardiovascular and pulmonary effects of morphine in conscious pigs, Am J Physiol, 261, R1286

10.1073/pnas.83.18.7114

McNally GP, 2002, Neuropsychopharmacology: The fifth generation of progress, 35

10.1126/science.179.4077.1011

10.1111/j.1476-5381.1980.tb10422.x

10.1016/S0165-6147(00)01843-5

Sofuoglu M, 1991, Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: Evidence for delta opioid receptor subtypes, J Pharmacol Exp Ther, 257, 676

10.1073/pnas.89.24.12048

10.1016/0014-5793(93)81011-N

10.1073/pnas.90.14.6736

10.1177/107385840100700307

10.1054/npep.2002.0900

10.1016/S1046-2023(02)00094-4

10.1002/1097-0282(2000)55:4<334::AID-BIP1006>3.0.CO;2-S

10.1038/258577a0

10.2174/1568026043451618

10.2174/1568015013358581

10.1017/CBO9780511549571

Gutstein HB, 2001, Goodman and Gilman's the pharmacological basis of therapeutics, 569

10.1146/annurev.pa.26.040186.000423

10.1016/0014-5793(94)00561-3

10.1038/377532a0

10.1016/0196-9781(83)90047-5

10.1073/pnas.73.8.2895

10.1038/386499a0

10.1073/pnas.76.12.6666

10.1073/pnas.86.13.5188

10.1515/bchm2.1979.360.2.1211

10.1016/S0014-5793(01)03042-3

10.2174/1568026043451663

10.2174/0929867024606731

10.1016/S0006-291X(85)80196-0

10.1073/pnas.80.19.5871

10.1124/jpet.102.039750

10.1002/med.2610090306

10.1016/0014-2999(81)90364-2

10.1016/0014-5793(88)80444-7

10.1073/pnas.89.24.11871

10.1021/jm980724

Pardridge WM, 1993, Introduction to the blood–brain barrier

10.1111/j.1748-1716.1963.tb02652.x

10.1016/0006-8993(70)90324-0

1991 Raven Press New York WM Pardridge AG de Boer ICJ van der Sandt PJ Gaillard Peptide drug delivery to the brainAnn Rev Pharmacol Toxicol 629 656

Greig NH, 1988, Delivery of human interferon‐alpha to brain by transient osmotic blood–brain barrier modification in the rat, J Pharmacol Exp Ther, 245, 581

10.1097/00006123-200201000-00014

10.1016/S0196-9781(97)00242-8

10.1016/S0169-409X(96)00423-1

10.1002/(SICI)1098-1136(199709)21:1<2::AID-GLIA2>3.0.CO;2-C

10.1152/ajplegacy.1976.230.1.94

10.1016/S0006-8993(99)01755-2

10.1152/physrev.1993.73.3.489

10.1126/science.7350645

10.1021/js980062b

Terasaki T, 1989, Absorptive‐mediated endocytosis of a dynorphin‐like analgesic peptide, E‐2078 into the blood–brain barrier, J Pharmacol Exp Ther, 251, 351

10.1046/j.1471-4159.2003.01582.x

Tamai I, 1997, Structure‐internalization relationship for adsorptive‐mediated endocytosis of basic peptides at the blood–brain barrier, J Pharmacol Exp Ther, 280, 410

10.1517/14712598.1.5.773

10.1016/0169-409X(95)00007-T

10.1126/science.1529356

10.1034/j.1399-3011.1999.00071.x

10.1124/jpet.102.037135

10.1016/S0168-3659(99)00196-0

10.1021/js980084y

Alyautdin R, 1995, Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80‐coated poly(butyl cyanoacrylate) nanoparticles, Eur J Pharm Biopharm, 41, 44

10.1016/S0196-9781(97)00474-9

10.1023/A:1018947208597

10.1023/A:1022604120952

10.1016/0006-2952(91)90616-D

10.2174/0929867013372535

10.1016/S0885-3924(02)00531-6

10.1191/0968130201pr183ra

10.1016/S0960-894X(97)00395-8

10.1016/S0378-5173(97)00328-1

10.1016/S0928-0987(02)00078-7

10.1021/jm9910167

Lis H, 1993, Protein glycosylation. Structural and functional aspects, Eur J Biochem, 3, 97

10.1016/0169-328X(94)90222-4

10.1016/S1074-5521(96)90064-2

10.1002/(SICI)1521-3773(19990517)38:10<1414::AID-ANIE1414>3.0.CO;2-L

Seitz O, 2000, Glycopeptide synthesis and the effects of glycosylation on protein structure and activity, Chem Biochem, 1, 214

10.1021/cr990308c

10.1111/j.1399-3011.1988.tb00906.x

10.1016/0304-3940(89)90446-1

10.1111/j.1399-3011.1987.tb03344.x

10.1111/j.1399-3011.1988.tb00908.x

10.1111/j.1399-3011.1993.tb00456.x

10.1111/j.1399-3011.1994.tb00537.x

10.1002/hlca.19910740505

10.1002/anie.198201553

10.1016/S0065-2318(08)60068-2

10.1021/jo005712m

Pardridge WM, Brain drug targeting: The future of brain drug development, 2001

10.1073/pnas.91.15.7114

10.1016/0006-291X(83)90318-2

10.1016/S0006-8993(00)02794-3

Egleton RD, 2001, Improved blood–brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation, J Pharmacol Exp Ther, 299, 967

10.1021/jm000077y

10.1124/jpet.104.069393

Adam G, 1968, Structural chemistry and molecular biology, 198

Rajashekhar B, 1986, Design of biologically‐active peptides with nonpeptidic structural elements—Biological and physical‐properties of a synthetic analog of beta‐endorphin with unnatural amino‐acids in the region 6‐12, J Biol Chem, 261, 3617, 10.1016/S0021-9258(18)67065-6

10.1021/ja0268635

10.1016/S0014-2999(02)01812-5

10.1016/0306-3623(92)90315-B

10.1002/syn.890110107

O'Neill SJ, 1997, Antagonistic modulation between the delta opioid agonist BW373U86 and the mu opioid agonist fentanyl in mice, J Pharm Exp Ther, 282, 271

10.1515/bchm2.1979.360.2.1211

10.1039/p19910001755

10.1073/pnas.94.17.9469

10.1021/jm970119r

10.1021/jm9810699

10.1021/ja9542911

10.1016/0003-9861(83)90055-3

10.1021/bi00368a075

10.1016/0024-3205(80)90266-0

10.1021/ja00413a035

10.1111/j.1399-3011.1989.tb01012.x

Blanc JP, 1983, Examination of the requirement for an amphiphilic helical structure in beta‐endorphin through the design, synthesis, and study of model peptides, J Biol Chem, 258, 8277, 10.1016/S0021-9258(20)82061-4

Taylor JW, 1983, Characterization of an amphiphilic helical structure in β‐endorphin through the design, synthesis, and study of model peptides, J Biol Chem, 258, 4464, 10.1016/S0021-9258(18)32646-2

10.1016/0076-6879(87)54091-5

10.1021/jm0202021

10.1073/pnas.83.16.5774

10.1358/dof.2001.026.06.668342

10.1016/S0957-4166(99)00544-3

10.1002/bip.20030

10.1021/jm0304616

10.1016/j.tips.2003.10.010

10.1016/j.tetasy.2004.11.038

10.1016/0041-0101(93)90375-S

Thông tin
Thông tin xuất bản

Medicinal Research Reviews

Tập 25 Số 5

557-585

Thông tin tác giả